inclusion criteria: * male or female at least 12 years of age * at high risk of progressing to severe covid-19 illness due to having one of the following underlying conditions and/or sociodemographic risk factors: 1. age ≥ 55 years (with or without comorbidities), 2. body mass index (bmi) ≥30 kg/m² if ≥ 18 years of age or bmi ≥85th percentile for age and gender based on cdc growth charts, 3. chronic kidney disease, 4. diabetes, 5. immunosuppressive disease, 6. currently receiving immunosuppressive treatment, 7. cardiovascular disease (including congenital heart disease) or hypertension, 8. chronic lung disease (e.g., chronic obstructive pulmonary disease, moderate-to-severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension), 9. sickle cell disease, 10. neurodevelopmental disorders or other conditions that confer medical complexity. * positive test for sars-cov-2 by rt-pcr or validated rapid antigen test within 72 hours prior to enrollment in the trial (positive sample must be collected within 72 hours prior to enrollment). * presence of symptoms consistent with mild or moderate covid-19 in the judgment of the investigator. * onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (headache/head congestion, throat symptoms, nasal symptoms, chest symptoms, cough). * willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of all protocol procedures.

inclusion criteria: * male or female at least 12 years of age * at high risk of progressing to severe covid-19 illness due to having one of the following underlying conditions and/or sociodemographic risk factors: 1. age ≥ 55 years (with or without comorbidities), 2. body mass index (bmi) ≥30 kg/m² if ≥ 18 years of age or bmi ≥85th percentile for age and gender based on cdc growth charts, 3. chronic kidney disease, 4. diabetes, 5. immunosuppressive disease, 6. currently receiving immunosuppressive treatment, 7. cardiovascular disease (including congenital heart disease) or hypertension, 8. chronic lung disease (e.g., chronic obstructive pulmonary disease, moderate-to-severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension), 9. sickle cell disease, 10. neurodevelopmental disorders or other conditions that confer medical complexity. * positive test for sars-cov-2 by rt-pcr or validated rapid antigen test within 72 hours prior to enrollment in the trial (positive sample must be collected within 72 hours prior to enrollment). * presence of symptoms consistent with mild or moderate covid-19 in the judgment of the investigator. * onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (headache/head congestion, throat symptoms, nasal symptoms, chest symptoms, cough). * willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of all protocol procedures.

inclusion criteria: male or female at least 12 years of age at high risk of progressing to severe covid-19 illness due to having one of the following underlying conditions and/or sociodemographic risk factors: age ≥ 55 years (with or without comorbidities), body mass index (bmi) ≥30 kg/m² if ≥ 18 years of age or bmi ≥85th percentile for age and gender based on cdc growth charts, chronic kidney disease, diabetes, immunosuppressive disease, currently receiving immunosuppressive treatment, cardiovascular disease (including congenital heart disease) or hypertension, chronic lung disease (e.g., chronic obstructive pulmonary disease, moderate-to-severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension), sickle cell disease, neurodevelopmental disorders or other conditions that confer medical complexity. positive test for sars-cov-2 by rt-pcr or validated rapid antigen test within 72 hours prior to enrollment in the trial (positive sample must be collected within 72 hours prior to enrollment). presence of symptoms consistent with mild or moderate covid-19 in the judgment of the investigator. onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (headache/head congestion, throat symptoms, nasal symptoms, chest symptoms, cough). willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of all protocol procedures.

inclusion criteria: male or female at least 12 years of age at high risk of progressing to severe covid-19 illness due to having one of the following underlying conditions and/or sociodemographic risk factors: age ≥ 55 years (with or without comorbidities), body mass index (bmi) ≥30 kg/m² if ≥ 18 years of age or bmi ≥85th percentile for age and gender based on cdc growth charts, chronic kidney disease, diabetes, immunosuppressive disease, currently receiving immunosuppressive treatment, cardiovascular disease (including congenital heart disease) or hypertension, chronic lung disease (e.g., chronic obstructive pulmonary disease, moderate-to-severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension), sickle cell disease, neurodevelopmental disorders or other conditions that confer medical complexity. positive test for sars-cov-2 by rt-pcr or validated rapid antigen test within 72 hours prior to enrollment in the trial (positive sample must be collected within 72 hours prior to enrollment). presence of symptoms consistent with mild or moderate covid-19 in the judgment of the investigator. onset of symptoms no more than 72 hours before enrollment in the trial. onset of symptoms is defined as the earlier of the first time at which the subject experienced subjective fever or any respiratory symptom (headache/head congestion, throat symptoms, nasal symptoms, chest symptoms, cough). willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of all protocol procedures.